Page 27 - Pharmaceutical Firms

Dr Reddy's acquire Eton Pharma's injectable products for $50 million

Under the terms of the agreement, Dr Reddy's acquired the Eton portfolio for an upfront payment of approximately USD 5 million in cash, besides contingent payments of up to USD 45 million

CBI arrests Jt Drug Controller, Biocon Biologics execs over fishy approvals

All five apprehended will be presented in court on Tuesday afternoon, agency to seek police custody

Zydus Lifesciences' Rs 750 cr-share buyback open between June 23-July 6

The drug firm, earlier known as Cadila Healthcare, has fixed July 15, 2022 as the last date for the settlement of bids on stock exchanges which may even happen early, as per a regulatory filing.

Near-term growth issues and cost pressure could impact Aurobindo Pharma

While valuations are now attractive, product approvals and progress on the injectable guidance are among key long-term term triggers

WEF 2022: Pfizer commits medicines, vaccines to 45 lower-income countries

World Economic Forum (WEF) 2022: The initiative by Pfizer was launched at the World Economic Forum Annual Meeting in Davos 2022

Bayer CropScience Q4 net profit surges over two-fold; revenue rises 31%

In the fourth quarter of 2021-22, the company's revenue from operations witnessed a growth of 31.29 per cent to Rs 963.3 crore compared to Rs 733.7 crore in corresponding quarter of the previous year

Ipca Labs Q4 net profit declines 19% at Rs 130 crore on higher expenses

The company had posted a consolidated net profit after tax of Rs 161.34 crore in the same quarter previous fiscal, Ipca Laboratories said in a regulatory filing

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

Zydus Lifesciences Q4 profit dips 41% to Rs 397 cr due to higher expenses

The company had posted a consolidated net profit of Rs 679 crore in the same quarter of previous fiscal year, Zydus Lifesciences said in a regulatory filing.

Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

Paradeep Phosphates IPO gets 29% subscription; retail portion booked 57%

The initial public offer of Paradeep Phosphates was subscribed 29 per cent on the first day of subscription on Tuesday. The IPO received bids for 7,86,87,000 shares against 26,86,76,858 shares on offer, according to data available with NSE. The category for Retail Individual Investors (RIIs) was subscribed 57 per cent and the portion for non-institutional investors attracted 6 per cent subscription. The Initial Public Offer (IPO) has a fresh issue of equity shares aggregating to Rs 1,004 crore and an offer for sale of up to 11,85,07,493 equity shares. As part of the OFS, Zuari Maroc Phosphates Pvt Ltd (ZMPPL) will offload 60,18,493 equity shares and the government of India will sell up to 11,24,89,000 equity shares. The government will be offloading its entire 19.55 per cent stake in the company. Currently, ZMPPL holds 80.45 per cent stake and the government of India owns the rest 19.55 per cent stake in the company. The price range for the offer is at Rs 39-42 per share. On Fr

Biological E plans to ramp up non-vaccines business in next three years

The privately held company has a turnover of about Rs 1,000 crore, of which close to 70-80 per cent come from the vaccines business now

Strong chemicals business outlook likely to support the SRF stock

This could aid overall profitability, even though other segments may see margin moderation

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

Glenmark gets tentative nod from USFDA for generic psoriasis foam

Glenmark Pharmaceuticals on Monday said its US-based arm has received tentative approval from the US health regulator for its generic Calcipotriene and Betamethasone Dipropionate foam used to treat psoriasis. The tentative approval granted to Glenmark Pharmaceuticals Inc, USA (Glenmark) by the US Food & Drug Administration (USFDA) is for Calcipotriene and Betamethasone Dipropionate foam of strength 0.005 per cent/0.064 per cent, the company said in a statement. It is the generic equivalent of Leo Pharma AS' Enstilar foam, it added. Citing IQVIATM sales data for the 12 months ended March 2022, the company said Enstilar foam, 0.005 per cent/0.064 per cent achieved annual sales of approximately USD 115.2 million. Glenmark said its current portfolio consists of 174 products authorised for distribution in the US marketplace and 48 abbreviated new drug applications (ANDAs) are pending approval with the USFDA.

Venus Remedies dispatches first batch of essential medicines to Ukraine

The company has launched a social media campaign to motivate people in India and abroad to make voluntary contributions for the cause

CCI approves deal to acquire minority stake in BDR Pharmaceuticals

BDR Pharmaceuticals is mainly into four therapeutic segments -- oncology, critical care, gynaecology, and neurology

Mankind Pharma forays into agri-tech space, plans to invest Rs 200 crore

Mankind Pharma on Monday announced its foray into the agri-tech segment, with plans to invest up to Rs 200 crore in the first two to three years

Pharma SMEs stock up on a month's raw material amid supply disruptions

The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players.

Strong specialty sales and volumes keep it sunny for Sun Pharma

Rerating on the cards; the domestic business is expected to outperform